- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02465944
A Pilot Study of FFP104 in Subjects With Crohn's Disease
August 23, 2016 updated by: Fast Forward Pharmaceuticals
A Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of FFP104 in the Treatment of Subjects With Moderate to Severely Active Crohn's Disease
This study will be conducted to evaluate the safety, tolerability and efficacy of intravenously administered FFP104 or placebo over 15 days (3 total doses) in subjects with moderate to severely active Crohn's Disease
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
24
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Leuven, Belgium, 3000
- Recruiting
- Universitair Ziekenhuis Leuven
-
Contact:
- Gert van Assche, Prof. Dr.
- Phone Number: +32 16 34 42 25
-
-
-
-
-
Rotterdam, Netherlands, 3015CE
- Recruiting
- Erasmus Medical Center
-
Contact:
- Janneke van der Woude, Prof. Dr.
- Phone Number: +31 107040126
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria
Subjects will be entered into this study only if they meet all of the following criteria:
- Willing and able to provide written informed consent.
- Willing and able to comply with all study procedures and visits.
- Male or female aged between 18 and 75 years, inclusive.
- Body Mass Index (BMI) between 18-35 kg/m2.
- Clinical diagnosis of Crohn's disease involving the colon and/or ileum for at least 3 months from Screening confirmed by radiological, endoscopic or histological evidence.
- Active Crohn's disease defined as a Crohn's Disease Activity Index (CDAI) score from 220 and 450, inclusive, at Screening.
- Active inflammatory disease as defined by Crohn's Disease Endoscopic Index of Severity (CDEIS) ≥ 8 (as determined by a Central Blinded Reader) at Screening.
- Tumor Necrosis Factor (TNF)-naïve or previously exposed to a single anti-TNF agent (such as infliximab, adalimumab or certolizumab pegol) with treatment discontinued at least 8 weeks prior to Screening due to inadequate response, loss of response or intolerance as judged by the Investigator.
- Must have adequate renal and hepatic function as adjudged by the Investigator.
- In good health (other than Crohn's disease) as evidenced by medical history and physical examination.
Exclusion criteria
Subjects will be entered into this study only if they meet none of the following criteria:
- Subjects who are pregnant, breastfeeding, or of child-bearing potential and not using a medically accepted form of contraception.
- Presence of fistulas, ileostomies, colostomies or rectal pouches or history of proctocolectomy or total colectomy. Subject has an ostomy or ileoanal pouch (subjects with a previous ileorectal anastomosis are not excluded).
- Subject has short bowel syndrome as determined by the Investigator.
- History of evidence of colonic mucosal dysplasia.
- Subject currently has a significant mechanical obstruction (stenosis).
- Subject has a current diagnosis of ulcerative or indeterminate colitis.
- Immunization with a live vaccine within 4 weeks of Screening, with the exception of influenza vaccine and no planned immunizations within the period of the study.
- Active or latent tuberculosis (TB) or tuberculosis infection; TB assessment and prophylaxis will be performed as per local biologicals regulations and guidelines.
- Subjects with a history of or ongoing chronic or recurrent infectious disease within the 12 months prior to Screening.
- Positive stool culture for Clostridium within the last 6 months prior to Screening.
Use of prohibited medications/procedures, including;
- Concomitant corticosteroids doses exceeding 20 mg/day of prednisone (equivalent)
- Concomitant use of budesonide
- Concomitant use of anti-TNF therapy
- Subjects who received previous treatment with more than one anti-TNF agent
- Concomitant use of cyclosporine, tacrolimus, sirolimus or mycophenolate mofetil
- Prior or concomitant use of anti-α4 integrin or other non-TNF blocking biological
- Use of tube or enteral feeding, elemental diet, or parenteral alimentation started within 2 weeks prior to Screening
- Leukocytapheresis or granulocytapheresis within 2 weeks prior to Screening
- Use of any prescription medications/products (with the exception of prescription medications for contraception and/or medications deemed acceptable by the Investigator and Sponsor).
- Use of any over the counter (OTC), non-prescription preparations (including vitamins, minerals, phytotherapeutic/herbal/plant-derived preparations) within 7 days prior to the Check-in visit (Day 0), unless deemed acceptable by the Investigator and Sponsor.
- Current or recent history (within 6 months of screening) of drug or substance abuse, including alcohol ≥ 14 units per week or who have a significant history of alcoholism or drug/chemical abuse within 6 months prior to the Screening visit (one unit of alcohol equals 0.5 pint [285 mL] of beer or lager, one glass [125 mL] of wine, or 1 shot [25 mL] of spirits).
- Subjects with known clinically significant cardiac disease (e.g., myocardial infarction or stroke within 6 months prior to Screening, unstable angina, claudication, etc.), or evidence of a clinically significant electrocardiogram (ECG) abnormality at Screening.
- A history of significant neurologic, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary or metabolic disease within 30 days of the Screening visit, as judged by the Investigator.
- Have a family history (more than one first degree relative) of multiple thrombotic events or a personal history of any venous or arterial thrombotic event including deep vein thrombosis, stroke, myocardial infarction, pulmonary embolus, and peripheral arterial thromboembolic events.
- Subject has had a positive hepatitis panel (including hepatitis B surface antigen [HBsAg], hepatitis B core antibody, and hepatitis C virus antibody [anti-HCV]) or a positive HIV antibody screen at time of Screening.
- Evidence of hepatic dysfunction, viral hepatitis, or current or chronic history of liver disease including non-alcoholic steatohepatitis (NASH) or abnormal hepatic markers (AST, ALT, ALP, or total bilirubin > 1.5 x upper limit of normal) at the time of the Screening visit.
- Abnormal renal function (BUN or creatinine >1.25 x upper limit of normal) at the time of the Screening visit.
- White Blood Cells <4 x 103/mm3; platelets <150 x 103/mm, hemoglobin < 6.2 mmol/L at the time of the Screening visit.
- Subjects with evidence of other serious, significant, acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study.
- History of malignancy, with the exception of resected basal cell carcinoma, squamous cell carcinoma of the skin, or resected cervical atypia or carcinoma in situ.
- Active acute infection requiring systemic treatment for more than 2 weeks.
- Planned surgery during the study period or have undergone major surgery within the 3 months prior to the Screening visit.
- Subjects who have received any investigational drug within 60 days or use of other experimental anti-CD therapies within the last 30 days prior to Screening visit.
- Known sensitivity to any component of the study drug or previous sensitivity reaction or other clinically significant reaction to intravenous medications or biologic therapy.
- Subjects who have previously received FFP104 or have been previously enrolled in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
|
Three intravenous infusions of 0.9% Saline over 15 days (d0, d7 and d14)
|
EXPERIMENTAL: FFP104 - 2.5 mg/kg
FFP104
|
Three intravenous infusions of FFP104 over 15 days (d0, d7 and d14)
|
EXPERIMENTAL: FFP104 - 5.0 mg/kg
FFP104
|
Three intravenous infusions of FFP104 over 15 days (d0, d7 and d14)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety and tolerability will be assessed through clinical laboratory tests, vital signs, physical exams, and adverse event assessments
Time Frame: Up to 84 days
|
Up to 84 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects achieving clinical response (decrease of Crohn's Disease Activity Index (CDAI) score by ≥100 points from baseline)
Time Frame: Days 0, 7, 14, 28, 42 and 84
|
Days 0, 7, 14, 28, 42 and 84
|
|
Proportion of subjects achieving clinical remission (attainment of absolute CDAI score of 150 points or less from baseline)
Time Frame: Days 0, 7, 14, 28, 42 and 84
|
Days 0, 7, 14, 28, 42 and 84
|
|
Proportion of subjects achieving partial response (decrease of CDAI score by >70 points from baseline)
Time Frame: Days 0, 7, 14, 28, 42 and 84
|
Days 0, 7, 14, 28, 42 and 84
|
|
Difference in CDAI score between FFP104 treated subjects and placebo subjects in each arm of the study
Time Frame: Days 0, 7, 14, 28, 42 and 84
|
Days 0, 7, 14, 28, 42 and 84
|
|
Time to response (decrease in CDAI score by >100 points)
Time Frame: Days 0, 7, 14, 28, 42 and 84
|
Days 0, 7, 14, 28, 42 and 84
|
|
Time to partial response (decrease of CDAI score by >70 points)
Time Frame: Days 0, 7, 14, 28, 42 and 84
|
Days 0, 7, 14, 28, 42 and 84
|
|
Change from baseline in Crohn's Disease Endoscopic Index of Severity (CDEIS)
Time Frame: Day 42
|
Day 42
|
|
Change from baseline in gut tissue organisation (histology)
Time Frame: Day 42
|
Day 42
|
|
Percent change from baseline in faecal calprotectin level
Time Frame: Day 42
|
Day 42
|
|
Percent change from baseline in C-Reactive Protein (CRP) levels
Time Frame: Day 7, 14, 28, 42 and 84
|
Day 7, 14, 28, 42 and 84
|
|
Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ)
Time Frame: Day 42
|
Day 42
|
|
Change from baseline in health outcome measures
Time Frame: Day 42
|
Health outcome measures that will be used are Short Form 36 (SF36), the EuroQol EQ-5D-5L and the Work Productivity and Activity Impairment Questionnaire Crohn's Disease (WPAI-CD)
|
Day 42
|
To evaluate changes from baseline in serum FFP104 levels
Time Frame: up to 84 days
|
up to 84 days
|
|
To evaluate changes in lymphocyte sub-populations in peripheral blood
Time Frame: Day 0, 14 and 42
|
Day 0, 14 and 42
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2016
Primary Completion (ANTICIPATED)
August 1, 2017
Study Completion (ANTICIPATED)
December 1, 2017
Study Registration Dates
First Submitted
May 18, 2015
First Submitted That Met QC Criteria
June 4, 2015
First Posted (ESTIMATE)
June 9, 2015
Study Record Updates
Last Update Posted (ESTIMATE)
August 24, 2016
Last Update Submitted That Met QC Criteria
August 23, 2016
Last Verified
August 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FFP104-002
- 2015-001678-17 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn's Disease
-
ProgenaBiomeRecruitingCrohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Crohn's | Crohn Disease of Ileum | Crohn Ileitis | Crohn's Disease Relapse | Crohns Disease Aggravated | Crohn Disease in Remission | Crohn's Disease of PylorusUnited States
-
Massachusetts General HospitalAmerican College of GastroenterologyNot yet recruitingInflammatory Bowel Diseases | Crohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's EsophagitisUnited States
-
Richard Burt, MDTerminatedCROHN'S DISEASEUnited States
-
Agomab Spain S.L.RecruitingFibrostenotic Crohn's DiseaseUnited States, Italy, Poland, Spain, Denmark, Austria, Canada, Germany
-
AbbVieActive, not recruitingCrohn's Disease (CD)United States, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, New Zealand, Norway, Poland, Romania, Slovakia, Spain, United Kingdom
-
AbbVieActive, not recruitingCrohn's Disease (CD)United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Romania, Russian Federation, Slo... and more
-
University Hospital, LilleMinistry of Health, FranceTerminatedCrohn's Disease AggravatedFrance
-
TakedaRecruitingCrohn's Disease (CD)United States, Australia, Israel, Belgium, Hungary, Canada, China, Croatia, Czechia, Greece, Italy, Japan, Korea, Republic of, Poland, United Kingdom, Lithuania, Slovakia, Spain
-
Weill Medical College of Cornell UniversityThe Kenneth Rainin FoundationRecruitingCrohn's Disease (CD)United States
Clinical Trials on FFP104
-
Fast Forward PharmaceuticalsUnknownPrimary Biliary CirrhosisNetherlands, United Kingdom